Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-06-14
2005-06-14
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S055100
Reexamination Certificate
active
06906044
ABSTRACT:
Methods of treating osteochondral lesions by the intraarticular application of a mixture of sodium hyaluronate and chondroitin sulfate are disclosed.
REFERENCES:
patent: 4486416 (1984-12-01), Soll et al.
patent: 4636524 (1987-01-01), Balazs et al.
patent: 4713448 (1987-12-01), Balazs et al.
patent: 4801619 (1989-01-01), Lindblad
patent: 5099013 (1992-03-01), Balazs et al.
patent: 5143724 (1992-09-01), Leshchiner et al.
patent: 5409904 (1995-04-01), Hecht et al.
patent: 5498606 (1996-03-01), Soll et al.
patent: 5929050 (1999-07-01), Petito
patent: 2002/0068718 (2002-06-01), Pierce
patent: 704216 (1996-04-01), None
patent: 0 875 248 (1998-11-01), None
patent: WO 96/32929 (1996-10-01), None
patent: WO 00/44367 (2000-08-01), None
Brown et al., “Gelatin/Chondroitin 6-Sulftae Microspheres for the Delivery of Therapeutic Proteins to the Joints,”Arthritis&Rheumatism, 41(12):2185-2195 (Dec. 1998).
Buckwalter et al., “The Increasing Need for Nonoperative Treatment of Patients with Osteoarthritis,”Clinical Orthopaedics and Related Research, 385:36-45 (2001).
Hardingham, “Chondroitin Sulfate and Joint Disease,”Osteoarthritis and Cartilage, 6 (Suppl A): 3-5 (1998).
Nerucci et al., “Effects of chondroitin sulfate and interleukin-1β on human chondrocyte cultures exposed to pressurization: a biochemical and morphological study,”Osteoarthritis and Cartilage8:279-287 (2000).
Watanabe et al., “Roles of Aggrecan, a Large Chondroitin Sulfate Proteoglycan, in Cartilage Structure and Function,”J. Biochem124:687-693 (1998).
Dr. Elias Hermida Ochoa et al., “Treatment of Osteochondral Lesions with Intraarticular Application of a Mixture of Hyaluronate and Sodium Chondroitin Sulfate”, May 2000.
Mark E. Adams, Guest Editor, “Viscosupplementation: A Treatment for Osteoarthritis”, An International Symposium, Ottawa, ON, Canada, Sep. 11, 1992, Introduction, The Journal of Rheumatology 1993, vol. 20, Supplement 39, p. 2.
Endre A. Balazs et al., “Viscosupplementation: A New Concept in the Treatment of Osteoarthritis”, The Journal of Rheumatology 1993, vol. 20, Supplement 39, pp. 3-9.
Jacques G. Peyron, “Intraarticular Hyaluronan Injections in the Treatment of Osteoarthritis: State-of-the-Art Review”, The Journal of Rheumatology 1993, vol. 20, Supplement 39, pp. 10-15.
Mark E. Adams, “An Analysis of Clinical Studies of the Use of Crosslinked Hyaluronan, Hylan, in the Treatment of Osteoarthritis”, The Journal of Rheumatology 1993, vol. 20, Supplement 39, pp. 16-18.
Jean-Pierre Pelletier et al., “The Pathophysiology of Osteoarthritis and the Implication of the Use of Hyaluronan and Hylan as Therapeutic Agents in Viscosupplementation”, The Journal of Rheumatology 1993, vol. 20, Supplement 39, pp. 19-24.
Vladimir Bobic, MD, “Autologous Chondrocyte Transplantation”, American Academy of Orthopaedic Surgeons Annual Meeting, Day 2-Mar. 16, 2000, pp. 1-6.
Joseph A. Buckwalter, MD, et al., “Restoration of Injured or Degenerated Articular Cartilage”, Journal of the American Academy of Orthopaedic Surgeons, vol. 2, No. 4, Jul./Aug. 1994, pp. 192-201.
Alcon Inc.
Copeland Barry L.
Krishnan Ganapathy
LandOfFree
Regeneration of articular cartilage damaged by grade I and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regeneration of articular cartilage damaged by grade I and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regeneration of articular cartilage damaged by grade I and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3471536